JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol details a method to isolate extracellular vesicles (EVs), small membranous particles released from cells, from as little as 10 μl serum samples. This approach circumvents the need for ultracentrifugation, requires only a few minutes of assay time, and enables the isolation of EVs from samples of limited volumes.

Abstract

Extracellular vesicles (EVs), membranous particles released from various types of cells, hold a great potential for clinical applications. They contain nucleic acid and protein cargo and are increasingly recognized as a means of intercellular communication utilized by both eukaryote and prokaryote cells. However, due to their small size, current protocols for isolation of EVs are often time consuming, cumbersome, and require large sample volumes and expensive equipment, such as an ultracentrifuge. To address these limitations, we developed a paper-based immunoaffinity platform for separating subgroups of EVs that is easy, efficient, and requires sample volumes as low as 10 μl. Biological samples can be pipetted directly onto paper test zones that have been chemically modified with capture molecules that have high affinity to specific EV surface markers. We validate the assay by using scanning electron microscopy (SEM), paper-based enzyme-linked immunosorbent assays (P-ELISA), and transcriptome analysis. These paper-based devices will enable the study of EVs in the clinic and the research setting to help advance our understanding of EV functions in health and disease.

Introduction

Extracellular vesicles (EVs) are heterogeneous membranous particles that range in size from 40 nm to 5,000 nm and are released actively by many cell types via different biogenesis routes1-9. They contain unique and selected subsets of DNA, RNA, proteins, and surface markers from parental cells. Their involvement in a variety of cellular processes, such as intercellular communication10, immunity modulation11, angiogenesis12, metastasis12, chemoresistance13, and the development of eye diseases9, is increasingly recognized and has spurred a great interest in their utility in diagnostic, prognostic, therapeutic, and basic biology applications.

EVs can be classically categorized as exosomes, microvesicles, apoptotic bodies, oncosomes, ectosomes, microparticles, telerosomes, prostatosomes, cardiosomes, and vexosomes, etc., based on their biogenesis or cellular origin. For example, exosomes are formed in multivesicular bodies, whereas microvesicles are generated by budding directly from plasma membrane and apoptotic vesicles are from apoptotic or necrotic cells. However, the nomenclature is still under refined, partly due to a lack of thorough understanding and characterization of EVs. Several methods have been developed to purify EVs, including ultracentrifugation14, ultrafiltration15, magnetic beads16, polymeric precipitation17-19, and microfluidic techniques20-22. The most common procedure to purify EVs involves a series of centrifugations and/or filtration to remove large debris and other cellular contaminants, followed by a final high-speed ultracentrifugation, a process that is expensive, tedious, and nonspecific14,23,24. Unfortunately, technological need for rapid and reliable isolation of EVs with satisfactory purity and efficiency is not yet met.

We have developed a paper-based immunoaffinity device that provides a simple, time- and cost-saving, yet efficient way to isolate and characterize subgroups of EVs22. Cellulose paper cut into a defined shape can be arranged and laminated using two plastic sheets with registered through-holes. In contrast to the general strategy to define the fluid boundary in paper-based devices by printing hydrophobic wax or polymers25-27, these laminated paper patterns are resistant to many organic liquids, including ethanol. Paper test zones are chemically modified to provide stable and dense coverage of capture molecules (e.g., target-specific antibodies) that have high affinity to specific surface markers on EV subgroups. Biological samples can be pipetted directly onto the paper test zones, and purified EVs are retained after rinse steps. Characterization of isolated EVs can be performed by SEM, ELISA, and transcriptomic analysis.

Access restricted. Please log in or start a trial to view this content.

Protocol

A general diagram of the operation procedure is provided in Figure 1. Using ethical practices, we collected blood samples from healthy subjects, and obtained aqueous humor samples from patients through the Taichung Veterans General Hospital (TCVGH), Taichung, Taiwan under IRB approved protocols (IRB TCVGH No. CF11213-1).

1. Fabrication of Paper Devices

  1. Cut chromatography paper into circles of 5 mm in diameter to provide the same layout as a 96-well microtiter plate. Sandwich these paper pieces with two polystyrene sheets with registered through-holes, and laminate.
  2. Modify paper devices using the chemical conjugation method described in the following steps28.
    1. Treat paper devices with oxygen plasma (100 mW, 1% oxygen, 30 sec) in a plasma chamber.
      CAUTION: Special caution must be taken when working with 3-mercaptopropyl trimethoxysilane and N-γ-maleimidobutyryloxy succinimide ester (GMBS), since they are both moisture sensitive and toxic. Wear protective gloves and avoid inhalation or contact with skin and eyes. Keep the stock bottle tightly closed and allow it to equilibrate to RT before opening to avoid water condensation. Alternatively, open the stock bottle inside a nitrogen-filled glove bag or box. Aliquot into small vials to avoid frequent opening of the stock bottle.
    2. Immediately incubate treated paper devices in a 4% (v/v) solution of 3-mercaptopropyl trimethoxysilane in ethanol (200 proof) for 30 min.
    3. Rinse paper devices with ethanol and incubate them with 0.01 μmol/ml GMBS in ethanol for 15 min.
    4. Rinse with ethanol (200 proof) and incubate paper devices with 10 µg/ml avidin solution in phosphate buffered saline (PBS) for 1 hr at 4 °C. Store at 4 °C if needed, and use within 4 weeks.
  3. Wet each paper test zones with 10 μl PBS containing 1% (w/v) bovine serum albumin (BSA) for 3 × 10 min before spotting 10 μl biotinylated capture molecules for 3 × 10 min. Use anti-CD63 antibody (20 μg/ml in PBS containing 1% (w/v) BSA and 0.09% (w/v) sodium azide) or annexin V (1:20, v/v in annexin V binding buffer) as capture molecules.
  4. Rinse off unbound anti-CD63 antibody or annexin V molecules using 10 μl corresponding PBS containing 1% (w/v) BSA or annexin V binding buffer solutions for 3 × 1 min, respectively.

2. Serum and Aqueous Humor Sample Collection and Processing

  1. Serum collection.
    1. Collect 10 ml of peripheral blood by venipuncture in serum separation tubes and gently invert the tube five times. Set the tube in a vertical position and wait for 30 min.
    2. Centrifuge at 1,200 × g for 15 min. Transfer the serum from the top layer to a clean tube, and centrifuge again at 3,000 × g for 30 min.
    3. Pass the supernatant through a 0.8 μm filter. Keep the sample at -80 °C until use.
  2. Aqueous humor collection: collect aqueous humor samples from patients diagnosed by an ophthalmologist directly through invasive procedures and store samples at -80 °C until use.

3. Isolation of Extracellular Vesicles

  1. Spot samples onto each paper test zone at a rate of 5 μl/min.
  2. Rinse off unbound EVs with 10 μl corresponding PBS containing 1% (w/v) BSA or annexin V binding buffer solutions for 3 × 1 min for paper devices functionalized with anti-CD63 antibody or annexin V molecules, respectively. Perform the following downstream assays.

4. Downstream Assay Example 1: Scanning Electromicrographs

  1. Fix EVs captured on functionalized paper test zone using 10 μl 0.5× Karnovsky’s fixative for 10 min.
  2. Rinse the samples with ample PBS for 2 × 5 min.
  3. Dehydrate the samples with subsequent 35% ethanol for 10 min, 50% ethanol for 2 × 10 min, 70% ethanol for 2 × 10 min, 95% ethanol for 2 × 10 min, and 100% ethanol for 4 × 10 min.
  4. Critical dry and sputter coat the samples with palladium/gold, and examine using an scanning electron microscope operated at low electron acceleration voltage (~ 5 kV).

5. Downstream Assay Example 2: Paper-based ELISA

  1. Add a 5 μl solution containing anti-CD9 primary antibody at 1:1,000 dilution in PBS to each test zone containing captured EVs. Wait 1  min.
  2. Rinse the samples with 30 ml PBS shaken at 100 rpm for 30 sec.
  3. Add a 5 μl solution containing horseradish peroxidase (HRP)-linked secondary antibody at 1:1,000 dilution in PBS and wait 1 min.
  4. Rinse the samples with 30 ml PBS shaken at 100 rpm for 30 sec.
  5. Add a 5 μl colorimetric substrate containing 1:1 volume ratio of hydrogen peroxide and 3,3’,5,5’-tetramethylbenzidine (TMB) and scan using a desktop scanner.

6. Downstream Assay Example 3: RNA Isolation

  1. Immerse the samples in 35 μl of polyvinylpyrrolidone-based RNA isolation aid and 265 μl of lysis/binding buffer to lyse EVs captured. Vortex vigorously.
  2. Add 30 μl homogenate provided in the isolation kit to the lysate. Vortex vigorously and put on ice for 10 min.
  3. Extract the RNA using acid phenol-chloroform separation described in the following steps.
    1. Take 330 μl of phenol-chloroform from the bottom layer of the bottle and add to the homogenate/lysate. Vortex vigorously.
    2. Centrifuge at 10,000 x g for 5 min. Transfer the aqueous (upper) phase to a clean tube and note the volume removed.
  4. Precipitate the total RNA with 100% ethanol of the volume that is 1.25 times the volume of the aqueous phase removed in the previous step and collect the RNA in the elution solution preheated to 95 °C.
  5. Concentrate and further purify the RNA using an RNA cleanup kit according to the manufacture’s protocol.

Access restricted. Please log in or start a trial to view this content.

Results

The ability of the paper device to isolate subgroups of EVs efficiently relies upon its sensitive and specific recognition of EV surface markers. The stable modification of paper fibers with capture molecules is achieved by using avidin-biotin chemistry as described elsewhere28-30. The effectiveness of chemical conjugation and that of the physisorption method is assessed using fluorescence-based readouts. The paper test zones are prepared following the protocol step 1) except the capture molecule is replaced w...

Access restricted. Please log in or start a trial to view this content.

Discussion

The most critical steps for successful isolation of subgroups of extracellular vesicles are: 1) a good choice of paper; 2) stable and high coverage of capture molecules on the surface of the paper fibers; 3) proper handling of samples; and 4) general laboratory hygiene practice.

Porous materials have been utilized in many inexpensive and equipment-free assays. They may have tunable pore size, versatile functionality, low cost and high surface-to-volume ratio permitting passive wicking of fluid...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported in part by the Taiwan National Science Council grants- NSC 99-2320-B-007-005-MY2 (CC) and NSC 101-2628-E-007-011-MY3 (CMC), and the Veterans General Hospitals and University System of Taiwan Joint Research Program (CC).

Access restricted. Please log in or start a trial to view this content.

Materials

NameCompanyCatalog NumberComments
Chromatography PaperGE Healthcare Life Sciences3001-861Whatman® Grade 1 cellulose paper
(3-Mercaptopropyl) trimethoxysilaneSigma Aldrich175617This chemical reacts with water and moisture and should be applied inside a nitrogen-filled glove bag. Avoid eye and skin contact. Do not breathe fumes or inhale vapors.
EthanolFisher ScientificBP2818Absolute, 200 Proof, molecular biology grade
Bovine serum albumin (BSA)BioShop Canada Inc.ALB001Often referred to as Cohn fraction V.
N-γ-maleimidobutyryloxy succinimide ester (GMBS)Pierce Biotechnology22309GMBS is an amine-to-sulfhydryl crosslinker. GMBS is moisture-sensitive.
AvidinPierce Biotechnology31000NeutrAvidin has 4 binding sites for biotin and its pI value is 6.3, which is more neutral than native avidin
Biotinylated mouse anti-human anti-CD63Ancell215-030clone AHN16.1/46-4-5
biotinylated annexin VBD Biosciences556418Annxin V has a high affinity for phosphatidylserine (PS)
Primary anti-CD9 and secondary antibodySystem BiosciencesEXOAB-CD9A-1The secondary antibody is horseradish peroxidise-conjugated
Serum separation tubesBD Biosciences367991Clot activator and gel for serum separation
Annexin V binding bufferBD Biosciences55645410x; dilute to 1x prior to use.
TMB substrate reagent setBD Biosciences555214The set contains hydrogen peroxide and 3,3’,5,5’-tetramethylbenzidine (TMB)
[header]
RNA isolation kitLife TechnologiesAM1560MirVana RNA isolation kit
Polyvinylpyrrolidone-based RNA isolation aidLife TechnologiesAM9690Plant RNA isolation aid contains polyvinylpyrrolidone (PVP) that binds to polysaccharides.
RNA cleanup kitQiagen Inc.74004MinElute RNA cleanup kit is designed for purification of up to 45 μg RNA.
Plasma chamberMarch InstrumentsPX-250
Scanning electron microscopeHitachi Ltd.S-4300
Desktop scannerHewlett-Packard CompanyPhotosmart B1108-bit color images were captured. Cameras and smart phones may be also used.
Image-record systemJ&H Technology CoGeneSys G:BOX Chemi-XX816-bit fluroscence images were captured. Fluroscence microscopes may be also used.

References

  1. Caby, M. P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., Bonnerot, C. Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17, 879-887 (2005).
  2. Lasser, C., et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J. Transl. Med. 9, 9(2011).
  3. Raj, D. A. A., Fiume, I., Capasso, G., Pocsfalvi, G. A multiplex quantitative proteomics strategy for protein biomarker studies in urinary exosomes. Kidney Int. 81, 1263-1272 (2012).
  4. Wiggins, R. C., Glatfelter, A., Kshirsagar, B., Brukman, J. Procoagulant activity in normal human-urine associated with subcellular particles. Kidney Int. 29, 591-597 (1986).
  5. Admyre, C., et al. Exosomes with immune modulatory features are present in human breast milk. J. Immunol. 179, 1969-1978 (2007).
  6. Keller, S., Ridinger, J., Rupp, A. K., Janssen, J. W. G., Altevogt, P. Body fluid derived exosomes as a novel template for clinical diagnostics. J. Transl. Med. 9, 86(2011).
  7. Asea, A., et al. Heat shock protein-containing exosomes in mid-trimester amniotic fluids. J. Reprod. Immunol. 79, 12-17 (2008).
  8. Bard, M. P., et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am. J. Resp. Cell Mol. Biol. 31, 114-121 (2004).
  9. Perkumas, K. M., Hoffman, E. A., McKay, B. S., Allingham, R. R., Stamer, W. D. Myocilin-associated exosomes in human ocular samples. Exp. Eye Res. 84, 209-212 (2007).
  10. Anderson, H. C., Mulhall, D., Garimella, R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab. Invest. 90, 1549-1557 (2010).
  11. Montecalvo, A., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 119, 756-766 (2012).
  12. Grange, C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 71, 5346-5356 (2011).
  13. Jaiswal, R., et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. Faseb. J. 26, 420-429 (2012).
  14. Thery, C., Clayton, A., Amigorena, S., Raposo, G. Current protocols in cell biology. Morgan, K. K. (UNIT 3.22), John Wiley. New York, NY. (2006).
  15. Rood, I. M., et al. Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int. 78, 810-816 (2010).
  16. Taylor, D. D., Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13-21 (2008).
  17. Witwer, K. W., et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracellular Vesicles. 2, 20360(2013).
  18. Fernandez-Llama, P., et al. Tamm-Horsfall protein and urinary exosome isolation. Kidney Int. 77, 736-742 (2010).
  19. Alvarez, M. L., Khosroheidari, M., Ravi, R. K., DiStefano, J. K. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 82, 1024-1032 (2012).
  20. Chen, C., et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab. Chip. 10, 505-511 (2010).
  21. Davies, R. T., et al. Microfluidic filtration system to isolate extracellular vesicles from blood. Lab. Chip. 12, 5202-5210 (2012).
  22. Chen, C., et al. Paper-based immunoaffinity devices for accessible isolation and characterization of extracellular vesicles. Microfluid. Nanofluid. 16, 849-856 (2014).
  23. Lamparski, H. G., et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods. 270, 211-226 (2002).
  24. Cantin, R., Diou, J., Belanger, D., Tremblay, A. M., Gilbert, C. Discrimination between exosomes and HIV-1: Purification of both vesicles from cell-free supernatants. J. Immunol. Methods. 338, 21-30 (2008).
  25. Carrilho, E., Martinez, A. W., Whitesides, G. M. Understanding wax printing: a simple micropatterning process for paper-based microfluidics. Anal. Chem. 81, 7091-7095 (2009).
  26. Dungchai, W., Chailapakul, O., Henry, C. S. Electrochemical detection for paper-based microfluidics. Anal. Chem. 81, 5821-5826 (2009).
  27. Glavan, A. C., et al. Omniphobic 'R-F paper' produced by silanization of paper with fluoroalkyltrichlorosilanes. Adv. Funct. Mater. 24, 60-70 (2014).
  28. Usami, S., Chen, H. H., Zhao, Y. H., Chien, S., Skalak, R. Design and construction of a linear shear-stress flow chamber. Ann. Biomed. Eng. 21, 77-83 (1993).
  29. Murthy, S. K., Sin, A., Tompkins, R. G., Toner, M. Effect of flow and surface conditions on human lymphocyte isolation using microfluidic chambers. Langmuir. 20, 11649-11655 (2004).
  30. Cras, J. J., Rowe-Taitt, C. A., Nivens, D. A., Ligler, F. S. Comparison of chemical cleaning methods of glass in preparation for silanization. Biosens. Bioelectron. 14, 683-688 (1999).
  31. Thery, C., Zitvogel, L., Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569-579 (2002).
  32. Scanu, A., et al. Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro- and anti-inflammatory cytokine production by high-density lipoproteins. J. Leukocyte Biol. 83, 921-927 (2008).
  33. Inal, J. M., et al. Microvesicles in health and disease. Arch. Immunol. Ther. Ex. 60, 107-121 (2012).
  34. Fridley, G. E., Holstein, C. A., Oza, S. B., Yager, P. The evolution of nitrocellulose as a material for bioassays. Mrs Bull. 38, 326-330 (2013).
  35. Gyorgy, B., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68, 2667-2688 (2011).
  36. Missoum, K., Belgacem, M. N., Bras, J. Nanofibrillated cellulose surface modification: a review. Materials. 6, 1745-1766 (2013).
  37. Kalia, S., Boufi, S., Celli, A., Kango, S. Nanofibrillated cellulose: surface modification and potential applications. Colloid Polym. Sci. 292, 5-31 (2014).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Extracellular VesiclesEVsPaper based DevicesImmunoaffinity PlatformEV IsolationEV CharacterizationScanning Electron MicroscopyP ELISATranscriptome AnalysisIntercellular CommunicationClinical Applications

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved